Swedish Orphan Biovitrum AB

Equities

SOBI

SE0000872095

Pharmaceuticals

Real-time Estimate Cboe Europe 07:09:06 2024-07-25 am EDT 5-day change 1st Jan Change
297.40 SEK +1.71% Intraday chart for Swedish Orphan Biovitrum AB +6.55% +10.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Morgan Stanley: Dupixent, New Launches to Drive Sanofi's Growth in Q2 MT
Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct CI
Transcript : Swedish Orphan Biovitrum AB, Q2 2024 Earnings Call, Jul 16, 2024
Swedish Orphan Biovitrum AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Swedish Orphan Biovitrum AB Updates Earnings Guidance for the Year 2024 CI
Sweden's Sobi Begins Rolling Application for Gout Treatment in US MT
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout CI
Sobi Wins EU Approval for Hemophilia A Drug Altuvoct MT
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A CI
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB CI
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment DJ
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member CI
Sobi Finalizes Inaugural SEK3 Billion Bond Issue MT
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy MT
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden MT
Transcript : Swedish Orphan Biovitrum AB, Q1 2024 Earnings Call, Apr 25, 2024
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024 CI
Certain Shares of Swedish Orphan Biovitrum AB are subject to a Lock-Up Agreement Ending on 14-MAR-2024. CI
Sobi to Expand in South Korea via Rare Disease JV with Handok MT
US Futures, European Stocks Mixed DJ
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox CI
Chart Swedish Orphan Biovitrum AB
More charts
Logo Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Employees
1,772
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
292.40SEK
Average target price
328.30SEK
Spread / Average Target
+12.28%
Consensus
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. News Swedish Orphan Biovitrum AB
  5. Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden